Company news
Dermata Therapeutics, Inc. news in 2021
Dermata Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions
November 18, 2021
Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea
November 16, 2021
Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 14, 2021
Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
November 11, 2021
Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
October 17, 2021
Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
September 26, 2021
Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer
August 31, 2021
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering
August 16, 2021
Decks in 2021
- IPO Roadshow (July 2021)
IPO roadshow · 31 slides · Jul 12, 2021